Treatment of Deep Venous Thrombosis with a Very Low Molecular Weight Heparin Fragment (CY 222)
| Autor: | S. Calen, Serise Jm, F. Toulemonde, A. Vallet, G. Dugrais, S. Winnock, G. Janvier, C. Vergnes, E. Dardel |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class medicine.medical_treatment Low molecular weight heparin Gastroenterology Capillary Permeability Physiology (medical) Internal medicine Humans Medicine Vein Aged Aged 80 and over Chemotherapy Hematologic Tests Heparin business.industry Anticoagulant Phlebography Hematology Thrombolysis Middle Aged Thrombophlebitis medicine.disease Thrombosis Molecular Weight Venous thrombosis medicine.anatomical_structure Anesthesia Female business medicine.drug |
| Zdroj: | Pathophysiology of Haemostasis and Thrombosis. 17:49-58 |
| ISSN: | 1424-8840 1424-8832 |
| DOI: | 10.1159/000215558 |
| Popis: | Thirty patients presenting with phlebographically confirmed deep venous thrombosis were treated with a very low molecular weight heparin fragment (CY 222) in an open and prospective phase-2 trial. A uniform dosage of 750 IC anti-factor Xa units/kg/day was administered subcutaneously for 10 days or more to patients whose thromboses were categorized as postsurgical (17 cases) or medical (13 cases). The clinical symptoms of venous thrombosis diminished in 93% of the patients overall. The extent of vascular clearing was assessed by an original scoring system which compared the pre- and posttreatment phlebo-graphies. The effect of treatment was globally rated ‘very good’ (more than 75 % lysis) in 37% of the patients, ‘good’ (about 50% lysis) in 40% and ‘poor’ (0–25% lysis) in 17%; the phle-bographic thrombosis worsened in 6.6%. Little change occurred in laboratory tests exploring thrombolysis, but a strong anti-factor Xa activity was detected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|